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Abstract
The failure of current strategies to provide an explanation for controversial findings on the pattern of pathophysiological
changes in Alzheimer’s Disease (AD) motivates the necessity to develop new integrative approaches based on multi-modal
neuroimaging data that captures various aspects of disease pathology. Previous studies using [18F]fluorodeoxyglucose
positron emission tomography (FDG-PET) and structural magnetic resonance imaging (sMRI) report controversial results
about time-line, spatial extent and magnitude of glucose hypometabolism and atrophy in AD that depend on clinical and
demographic characteristics of the studied populations. Here, we provide and validate at a group level a generative
anatomical model of glucose hypo-metabolism and atrophy progression in AD based on FDG-PET and sMRI data of 80
patients and 79 healthy controls to describe expected age and symptom severity related changes in AD relative to a
baseline provided by healthy aging. We demonstrate a high level of anatomical accuracy for both modalities yielding
strongly age- and symptom-severity- dependant glucose hypometabolism in temporal, parietal and precuneal regions and a
more extensive network of atrophy in hippocampal, temporal, parietal, occipital and posterior caudate regions. The model
suggests greater and more consistent changes in FDG-PET compared to sMRI at earlier and the inversion of this pattern at
more advanced AD stages. Our model describes, integrates and predicts characteristic patterns of AD related pathology,
uncontaminated by normal age effects, derived from multi-modal data. It further provides an integrative explanation for
findings suggesting a dissociation between early- and late-onset AD. The generative model offers a basis for further
development of individualized biomarkers allowing accurate early diagnosis and treatment evaluation.
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Introduction
Neuroimaging studies using [18F]fluorodeoxyglucose positron
emission tomography (FDG-PET) and structural magnetic reso-
nance imaging (sMRI) provide substantial evidence of high
sensitivity for early detection and progression assessment in
Alzheimer’s disease (AD) at a group and single subject level [1–
11]. However, among these studies there are a number of
discordant results in terms of spatial characteristics and magnitude
of glucose hypometabolism and atrophy [12–14]. The supposition
that age- and symptom severity-related variability are the main
cause for these discrepancies has motivated researchers to adopt
analytical strategies that split disease populations into subgroups
depending on age- or symptom-severity (e.g. early- and late-onset
AD) [12–14].
The question that needs to be answered is whether age and
symptom severity indeed account for most of these discrepancies.
In other words, what are the relative contributions of age and
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disease to the anatomical patterns of abnormality of structure and
function? Investigation of these relationships may also provide
clues to another long-time controversy – can the observed
differences between young and aged AD patients be regarded as
a continuum or is there a clear separation into two cohorts
dependent on separate pathological mechanisms?
Recent studies have suggested that AD related brain changes
may be similar to those associated with healthy aging. If so, this
could explain age overestimation determined from sMR images
from AD patients [15] and inaccuracies obtained with automated
classification-based computer diagnostics in the eldest healthy
controls and youngest AD patients [11]. However, these effects
can also be explained in a more simple way by the applied
methodology. Both AD and healthy aging have been linked to a
decrease in grey matter (GM) volume in extensive networks
covering substantial parts of the brain [16–18]. Partial overlaps
between these networks are therefore very likely and also occur in
some key regions for AD including the hippocampus and parietal
cortices. A statistical classification/prediction model trained either
for prediction of age or AD would therefore consider these regions
as important for separation/prediction. An older healthy control
would therefore have a higher probability to be misclassified as AD
when applying a classifier trained on younger AD subjects. In
contrast, age prediction in an AD patient using a model built on
healthy controls would result in an age overestimation in this
patient due to the partially overlapping network of reductions in
GM volume. Both predictions are fully in line with previous
findings [15,19].
Another controversially discussed issue is the relative capability
and sensitivity of FDG-PET and sMRI to detect AD related
pathology. Recent studies provided evidence for the superiority of
each of the two imaging modalities as compared to the other to
detect AD related pathology [10,20]. However, none of these
findings can be interpreted without serious methodical consider-
ations. Both studies restricted their analyses to univariate region-
of-interest statistics to determine the power of each modality to
discriminate between AD patients and control subjects. Although
this approach provides a good estimation of the differential
pathology in the region mostly affected by the disease, it does not
at all reflect the whole pattern of AD related pathology over the
whole brain. Yet, exactly this whole-brain pattern is crucial for
detection and differentiation of AD from healthy aging and other
neurodegenerative processes. A second methodological limitation
of previous studies is related to pre-processing of FDG-PET data.
These data are strongly affected by the underlying atrophy
pattern. A reduction in grey matter volume in a specific region
would therefore also lead to a reduction of the observed metabolic
signal due to increased contribution of other tissue types. This
effect is commonly known as partial volume effect (PVE) [21]. If
not accounted for, this effect strongly restricts the interpretation of
the observed FDG-PET signal due to a high susceptibility to the
underlying atrophy. A correction for this effect is therefore
necessary to enable a valid interpretation of the independent
contribution of both imaging modalities to detection of AD related
pathology.
To address these issues and questions we generate group level
anatomical models of pathophysiological changes observed in AD
using FDG-PET and sMRI data. In these models we account for
PVE and integrate disease-, age- and symptom severity-associated
changes in AD patients. We further dissociate them from healthy
aging related changes using a combination of voxel-based general
linear models (GLMs). We additionally assume that AD-induced
changes are added to changes observed in healthy aging. We use
the models to generate age- and symptom severity- specific whole-
brain patterns of glucose hypometabolism and atrophy. To
validate the obtained model and to address the questions described
above, we contrapose the models’ predictions in terms of
anatomical plausibility to findings reported in previous studies
investigating age- and AD-related changes. Thereby, we aim to
provide at a group level an integrative explanation for the
controversial findings described above regarding spatial charac-
teristics and magnitude of glucose hypometabolism and atrophy in
AD. We further make conclusions on the relative capability of
FDG-PET and sMRI to predict AD related pathology at a group
level.
We hypothesize, on the basis of the above considerations [12–
14] that a generative model predicting age and symptom severity
contributions to disease pathology based on data from two
imaging modalities – FDG-PET and sMRI – would provide a
robust and accurate differential pattern of glucose hypometabo-
lism and atrophy at different ages in AD patients. We expect
stronger changes in glucose metabolic compared to anatomical
data in earlier disease stages, in accordance with a recently
proposed model, which suggests that functional impairment
precedes structural changes in AD [22]. We also hypothesize that
patterns of brain atrophy associated with healthy aging would
overlap those associated with disease progression yet also show a
clearly distinguishable anatomical distribution pattern.
Methods
Subjects
To derive a generative model of age and symptom severity
related changes, we extracted from the Alzheimer’s disease
Neuroimaging Initiative (ADNI) database (www.adni-info.org)
sMRI and FDG-PET data from multiple centres of 80 patients
with a clinical diagnosis of AD and 79 healthy controls (Table 1). A
full list of subject and scan IDs used in this study is provided at the
following location: http://www.unil.ch/webdav/site/lren/shared/
Juergen/Overview_patandcon_MRIandPETdate.xlsx. For all sub-
jects, follow-up evaluations were available for up to 5 years after
initial examination. Control subjects and AD patient groups were
matched for gender and age. A diagnosis of AD was based on
NINCDS/ARDRA criteria [23]. Exclusion criteria for the ADNI
data included the presence of any significant neurological disease
other than AD, history of head trauma followed by persistent
Author Summary
Establishing an accurate diagnosis of Alzheimer’s disease
has been a major challenge in the past decades. With an
increasing amount of studies aiming at detection and
validation of imaging biomarkers for this disease, many
apparently controversial findings have been reported over
the time. The failure of current strategies to provide a
consistent explanation for these differential findings
motivates the necessity to develop new integrative
approaches based on multi-modal data that capture
various aspects of disease pathology. In our study we
propose such a generative model providing a compre-
hensive approach towards integration of previously
published differential findings in early- and late-onset
AD. We believe that our analytical strategy not only
provides the link between imaging biomarkers and clinical
phenotype considering the effects of aging, but could also
lead to new areas of research in terms of creation of new,
individualized biomarkers for a more accurate diagnosis of
Alzheimer’s disease.
Generative Biomarker Model in Alzheimer’s Disease
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neurological deficits or structural brain abnormalities, psychotic
features, agitation or behavioural problems within the previous
three months or a history of alcohol or substance abuse. For most
subjects, multiple follow-up FDG-PET and sMRI scans were
available. Only data from the first examination date were used for
analysis. The study was conducted according to the Declaration of
Helsinki. Written informed consent was obtained from all
participants before protocol-specific procedures were performed.
Data used in the preparation of this article were obtained from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(adni.loni.ucla.edu).
The ADNI was launched in 2003 by the National Institute on
Aging (NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration
(FDA), private pharmaceutical companies and non-profit organi-
zations, as a $60 million, 5- year public-private partnership. The
primary goal of ADNI has been to test whether serial magnetic
resonance imaging (MRI), positron emission tomography (PET),
other biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression of mild
cognitive impairment (MCI) and early Alzheimer’s disease (AD).
Determination of sensitive and specific markers of very early AD
progression is intended to aid researchers and clinicians to develop
new treatments and monitor their effectiveness, as well as lessen
the time and cost of clinical trials. The Principal Investigator of
this initiative is Michael W. Weiner, MD, VA Medical Center and
University of California – San Francisco. ADNI is the result of
efforts of many co-investigators from a broad range of academic
institutions and private corporations, and subjects have been
recruited from over 50 sites across the U.S. and Canada. The
initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to
participate in the research, approximately 200 cognitively normal
older individuals to be followed for 3 years, 400 people with MCI
to be followed for 3 years and 200 people with early AD to be
followed for 2 years.’’ For up-to-date information, see www.adni-
info.org.
sMRI data
The sMRI dataset included standard T1-weighted images
obtained with different scanner types using a 3D MP-RAGE
(magnetization-prepared 180 degrees radio-frequency pulses and
rapid gradient-echo) sequence varying in TR and TE (repetition
and echo time) with an in-plane resolution of 1.2561.25 mm and
1.2 mm slice thickness acquired at 1.5T magnetic field strength.
All raw data were pre-processed to correct for distortion and B1
non-uniformity as described on the ADNI webpage (http://www.
loni.ucla.edu/ADNI/Data/ADNI_Data.shtml).
FDG-PET data
We analysed FDG-PET data for subjects who also underwent
sMRI scans. FDG-PET data were acquired with different PET-
scanner types according to one of three different protocols: 1)
dynamic: a 30 min six-frame acquisition (6 five-minute frames),
with scanning from 30 to 60 min post FDG injection; 2) static: a
single-frame, 30 min acquisition with scanning 30–60 min post
injection; and 3) quantitative: a 60 min dynamic protocol
consisting of 33 frames, with scanning beginning at injection and
continuing for 60 min. The majority of the scans in the ADNI
study were acquired with the first acquisition protocol. Images
further differed in resolution, orientation, voxel and image
dimensions and count statistics. The frames from 30 to 60 minutes
post injection were spatially realigned to minimize inter-frame
motion artefacts and a mean image of these frames was calculated
for each subject. These mean images were used for further
analysis.
Image pre-processing
All data processing steps were carried out using the SPM5
software package (Statistical Parametric Mapping software:
http://www.fil.ion.ucl.ac.uk/spm/) implemented in Matlab 7.7
(MathWorks Inc., Sherborn, MA). The same pre-processing
algorithm was used for sMRI and FDG-PET data, as described
elsewhere [11]. This procedure includes co-registration and
interpolation of both FDG-PET and sMR images to an isotropic
resolution of 16161 mm3, bias correction for inhomogeneity
artefacts for sMRI data, segmentation of sMRI data into different
tissue classes (only the grey matter tissue class is used for further
analyses), and masking of non-GM voxels in FDG-PET data. PVE
correction using the modified Mu¨ller-Ga¨rtner method [21,24] was
in the PVElab software package [25] that is compatible with
SPM5 only. This procedure uses the segmented sMR images to
account for PVE and for potential atrophy effects in FDG-PET.
DARTEL (Diffeomorphic Anatomical Registration using Expo-
nentiated Lie algebra) based on grey matter tissue probability
maps was used for spatial normalization of data to an average size
template created from all study participants [26]. Structural MR
images were additionally modulated to preserve the total amount
of signal from each region. The same deformation matrices used to
normalise sMRI scans to a template were used to co-register the
FDG-PET images. After spatial normalization anatomical regions
of all subjects were located at same location in the images.
Smoothing with a Gaussian kernel of 12 mm FWHM (full width at
half maximum) accounted for minor misalignment errors.. FDG-
PET data were intensity normalized to cerebellar mean [27] and
masked to avoid big edge effects. The cerebellar region was chosen
for intensity normalization of FDG-PET as it has been shown to
be a region of choice for intensity normalization which is
unaffected in healthy aging and early stages of AD when
correcting for PVE caused by atrophy [27–29].
FDG-PET and sMRI models of healthy aging and AD
All statistical analyses were also carried out using the SPM5
software package and Matlab 7.7. The effect of aging in healthy
control subjects was estimated separately for FDG-PET and sMRI
with voxel-wise linear regressions. To obtain the healthy aging
component of our generative model we used the beta coefficients
of aging in healthy controls to simulate voxel-wise changes in both
imaging modalities for the age range 50 to 80 years (Figure 1a).
The estimated values at 50 years were used as a 100% baseline.
Estimated age-related changes for the whole age range for both
FDG-PET and sMRI were expressed as percent decreases relative
to this baseline.
Table 1. Subject group characteristics.
Controls AD T-test (df,t,p)
Number 79 80 -
Male/Female 41/38 40/40 -
Age (years) 75.864.9 75.767.0 157,0.1,.887
Age range (years) 62–87 55–88 -
MMSE (score) 28.761.6 23.662.2 157,16.6, .001
Mean 6 standard deviation. AD Alzheimer’s disease, con converters, MMSE Mini
Mental State Examination, noncon non-converters.
doi:10.1371/journal.pcbi.1002987.t001
Generative Biomarker Model in Alzheimer’s Disease
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To dissociate healthy aging- and AD-related changes, the
variance in glucose utilization and GM atrophy explained by
healthy aging was removed by voxel-wise linear regressions from
all imaging data used for further models (control subjects and AD
patients for both FDG-PET and sMRI; [19]). GLMs with age and
symptom severity (as measured by MMSE, [30]) as regressors were
built for the AD group separately for both FDG-PET and MRI.
To model the interaction of both factors the product of age and
symptom severity was also included. The inclusion of the
interaction between age and symptom severity accounts for any
differential disease progression associated with age in the AD
group. In this model we took the control group mean glucose
metabolism and GM volume at each voxel as a baseline. In an
effort to define the specific variance attributable to AD explained
by aging and symptom severity we removed variance from this
baseline that was explained by these factors and their interaction
(Figure 1c).
Further, we determined at what age the changes related to
normal aging become similar to those found in AD. For this
purpose, a third GLM, using age as the only factor, was calculated
in the AD cohort for both FDG-PET and sMRI data. The ages at
which the separate regressions for normal and AD associated
Figure 1. Schematic representation of voxel-wise age- and symptom severity- related models. a) Schematic representation of age-
related changes in one voxel (in %) considering GM volume at the age of 50 years as baseline. b) Schematic representation of changes related to
healthy aging (black line) and age-related differences in AD (red line) in one voxel. Intersection age (dotted line) represents the age at which healthy
aging in this voxel becomes similar to changes observed in AD. The hinge in the red line (aging in AD) at the intersection point indicates that after the
intersection age, according to our assumption of the additive impact of AD related processes to healthy aging, the healthy aging model would apply
in AD patients as no pathological processes in terms of atrophy or glucose hypometabolism are longer observable after this time point. c) Decrease
(in %) in GM volume observed in an exemplary voxel in AD depending on the constellation of age and symptom severity (MMSE) relative to the
baseline provided by healthy aging (violet line). AD Alzheimer’s disease, GM grey matter, MMSE Mini Mental State Examination.
doi:10.1371/journal.pcbi.1002987.g001
Generative Biomarker Model in Alzheimer’s Disease
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aging intersect (referred to as intersection ages) were calculated on
a voxel-wise basis (Figure 1b). To calculate these voxel-wise
intersection ages xage the linear regression equations for healthy
aging and aging in AD (yCon~xage:bConzcCon and
yAD~xage:bADzcAD, where yCon and yAD are the predicted
voxel-wise grey matter volumes/glucose metabolism, cCon and cAD
the corresponding intercepts and bCon and bAD the slopes of
regression lines in controls and AD respectively) were set equal and
resolved for xage. The intersection age xage is then given by:
xage~
cCon{cAD
bAD{bCon
:
Generally, an early intersection age indicates that a region is
relatively spared by AD, if healthy aging affects AD patients
similarly to controls. A higher intersection age suggests that the
region is predominantly affected by disease-related processes.
All three voxel-based models are based on a previously validated
assumption of linearity between healthy aging- and AD symptom
severity- related changes with FDG-PET and sMRI data. [16,31].
To exclude a more complex e.g., quadratic relationship between
age or symptom severity in the AD cohort we calculated further
regression analyses after removing variance explained by healthy
aging. These comprised a) including only linear relationships for
both age and symptom severity; b) additionally modelling
quadratic relationships with age; and c) additionally modelling a
quadratic relationship for symptom severity. Gender was included
as a covariate for both imaging modalities and total intracranial
volume was additionally included as a covariate for the sMRI data.
A significance threshold of 0.001 uncorrected at voxel-level and
0.05 family-wise error (FWE)-corrected for non-stationarity of
smoothness at cluster level was used for statistical analyses [32].
Statistical analysis of behavioural data
Group comparisons of AD patients and control subjects for age
and symptom severity were carried out using T-tests with a
significance threshold of p,.05. Group differences regarding
gender were evaluated using a chi-square test for independent
samples. The statistical analyses were performed with SPSS 17.0
(http://www.spss.com/statistics/). A Pearson’s correlation coeffi-
cient was calculated (p,.05) in the AD group to investigate the
relationship between age and symptom severity.
Results
Subject demographic characteristics
AD patients and control subjects did not differ in age
[t(157) = 0.1;p = .887]. As expected MMSE differed significantly
between the groups [t(157) = 16.6;p,.001]. The comparison of
AD patients and control subjects in relation to sex showed no
statistical differences [x2(1) = 0.06;p = .811].
Differential pattern of changes related to healthy aging
in FDG-PET and sMRI
The generative model for healthy aging based on sMRI reveals
a widespread pattern of grey matter volume reductions sparing
only bilateral dorsal primary sensorimotor regions, brainstem,
lateral thalamus and the dorsal part of caudate nucleus (Figure 2a).
We observe the greatest reductions in GM volume, of more than
10% per decade, in right superior parietal lobule, superior and
inferior frontal gyrus, inferior frontal sulcus, primary auditory
cortex, pars triangularis, and anterior hippocampus. Left-hemi-
spheric reductions are observed in the premotor cortex, and in
superior and middle frontal gyri. Bilateral GM volume reductions
are restricted to calcarine gyri, insulae, anterior cingulate cortex,
superior temporal sulcus and posterior hippocampus.
The equivalent FDG-PET based model demonstrates a specific
pattern of age-related metabolic changes with an age related
decrease in glucose utilization of more than 10% per decade in
bilateral parietal, occipital, sensorimotor, premotor, dorsolateral
prefrontal and anterior insular cortices. Additionally, we see a
major reduction in glucose metabolism in bilateral posterior
putamina and in the left dorsal caudate nucleus (Figure 1b).
Age- and symptom severity- related changes
We report a negative relationship between symptom severity
and both metabolism and GM volume (Figure 3) and (Figure 4).
Lesser reductions in glucose utilization and GM volume are
associated with greater age in AD patients.
Symptom severity related GM volume changes at age 60 years
were detected throughout the brain with greatest degrees of
atrophy seen in bilateral parietal, temporal, occipital, dorsolateral
prefrontal, posterior cingulate and premotor cortices, the precu-
neus, dorsal caudate nucleus, amygdala and hippocampus. At 80
years of age, the greatest, bilateral, symptom severity related
atrophy was found in parietal, temporal, occipital, primary
sensorimotor and dorsolateral prefrontal cortices, the hippocam-
pus and thalamus.
We show symptom severity- related glucose metabolism
reductions bilaterally in posterior temporal, parietal, lateral
occipital, dorsolateral prefrontal and premotor cortices and in
the precuneus. Symptom severity related hypometabolism is less
extensive at higher than lower ages.
In general, regional decreases in metabolism and grey matter
volumes relative to healthy aging are significantly more pro-
nounced in the lower compared to higher age range in AD. In the
model, we observe substantial age-dependant differences in terms
of hypometabolism and atrophy in AD patients compared to a
healthy aging baseline even at an MMSE score of 30. At the age of
60 years these differences are bilaterally restricted to inferior
frontal gyrus, premotor regions, inferior and medial temporal
gyrus, cerebellum, rectal gyrus and to left parietal regions. Regions
showing an initial difference in this age range do not correspond
well to the anatomical pattern observed in later symptom severity
stages and remain rather less affected compared to other regions.
Initial differences observed at the age of 80 years are located in
bilateral parietal, bilateral hippocampal and left sensorimotor
regions and in both caudate nuclei.
We observe a more consistent anatomical pattern of initial
differences in hypometabolism at a MMSE score of 30. For the
whole age range of 60–80 years, initial glucose hypometabolism is
observed in bilateral parietal, inferior temporal and posterior
cingulate cortices, posterior thalamus and the precuneus. Addi-
tionally, at 80 years of age we demonstrate significant differences
in bilateral primary sensorimotor and premotor regions and in the
anterior temporal lobes. All regions showing initial glucose
hypometabolism, except for the posterior thalamus, also show
the steepest symptom severity-related metabolic decline. Regions
hypometabolic only at age 80 show no specific symptom severity-
related decline.
Dissociating healthy aging from Alzheimer’s disease
To dissociate brain changes related to healthy aging from AD
pathology at specific ages we computed the intersection age of
models for healthy aging and aging in AD at the voxel level
(Figure 5). With sMRI, we see the highest intersection ages
bilaterally in hippocampus, anterior and posterior thalamus,
posterior and midcingulate, parietal, temporal, cerebellar, pre-
Generative Biomarker Model in Alzheimer’s Disease
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frontal and premotor regions. With FDG-PET, regions with the
highest intersection ages are bilaterally restricted to precuneus,
cerebellum, anterior and posterior cingulate, posterior parietal,
temporal, lateral occipital, primary motor, premotor and prefron-
tal cortices and the left dorsal caudate nucleus.
Linear relationship between age, symptom severity and
imaging results
With sMRI, the linear regression model describing the
relationship between age, symptom severity and structural changes
in AD showed a significant correlation for each factor with
atrophy (Figure 6a). After removing the variance attributable to
healthy aging, age correlates positively with GM volume in AD in
right premotor and bilaterally in parietal, temporal, occipital and
medial and lateral prefrontal regions. Additional significant
bilateral positive correlations were observed in anterior cingulate
cortex and in the cerebellum. These counter-intuitive positive
correlations can be interpreted as reflecting the additional age-
specific atrophy needed to produce a similar degree of symptom
severity in younger compared to older AD patients. There were no
significant negative correlations. Further, we found significant
bilateral positive correlations with symptom severity in temporal,
lateral and medial prefrontal, inferior parietal, occipital regions
and in thalamus as well as the left premotor cortex. Again no
negative correlations were observed.
With FDG-PET we found a significant positive correlation
between age and glucose metabolism in bilateral temporal and
parietal regions. There were no other significant correlations with
age or symptom severity.
Inclusion of a quadratic relationship with age or MMSE into the
models revealed significant positive correlations of glucose metab-
olism with a quadratic age coefficient only in left dorsal parietal
cortex (Figure 5b). No other significant correlations were observed.
Discussion
In this study we demonstrate that a generative model captures
the anatomical and metabolic features associated with AD and
Figure 2. Healthy aging related changes observed in MRI (a) and FDG-PET (b) considering the expression of GM volume and
glucose metabolism at the age of 50 years as baseline. FDG-PET [18F]fluorodeoxyglucose positron emission tomography, GM grey matter, MRI
structural magnetic resonance imaging.
doi:10.1371/journal.pcbi.1002987.g002
Figure 3. A linear model of age and MMSE related changes observed in AD in FDG-PET considering the healthy control group as
baseline. AD Alzheimer’s disease, FDG-PET [18F]fluorodeoxyglucose positron emission tomography, MMSE Mini Mental State Examination.
doi:10.1371/journal.pcbi.1002987.g003
Generative Biomarker Model in Alzheimer’s Disease
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healthy aging in the age range 60 to 80 years accurately and
robustly. The model differentiates between the effects of aging and
symptom severity in AD patients. It also provides a means to test
for interactions between them, as exemplified here with disease
progression and patient age. The age-dependant differential
sensitivity of structural and metabolic scanning for the detection
of AD pathology we demonstrate emphasises the ability of our
generative model to infer expected age- and symptom severity-
specific changes recorded with both imaging modalities.
Our study’s three main findings support and extend observa-
tions made previously. Firstly, the spatial location of changes
related to different ages and symptom severities in AD was mostly
consistent with regions reported in the literature [33–35].
However we also identified a more widespread network of regions
showing age related metabolic decreases and atrophy whilst
controlling for potential PVE related changes in FDG-PET. The
AD model at lower ages was substantially more extensive in terms
of decreases in glucose metabolism and GM volume than at
greater ages. This finding is in accordance with previous research
[12–14].
Our second result is that in general, the magnitude of healthy
aging related imaging changes between 50 and 80 years is
comparable to that of changes associated with an increase in AD
symptom severity at any age. Substantial regional overlap in both
hypometabolism and atrophy was observed between a network of
areas affected by healthy aging and that identified in AD. To
interpret this overlap it is important to note that all changes related
to age and symptom severity in AD we report here were calculated
after removing the variance explained by healthy aging. That
means that all age-related differences can be interpreted as an add-
on required to normal age-related changes to induce a predefined
symptom severity at the corresponding age. In previous research
comparing differently aged AD groups with age-matched healthy
control subjects a split of AD into different subgroups e.g., early-
and late-onset AD, was suggested [12]. In contrast, the results of
our study indicate that the anatomically different qualitative and
quantitative patterns observed in AD at different ages may be
explicable by regionally inhomogeneous, age-related, baseline
changes in healthy controls. This notion is supported by the
observation of a similar anatomical pattern of structural and
metabolic changes across the studied age range in AD patients.
Overall, our results suggest a more integrative view of AD
indicating that previously reported differences between early- and
late-onset AD patients can be explained as an interaction of AD
pathology with changes due to healthy aging. More simple,
assuming that AD affects parietal and temporal regions, a strong
healthy aging related decrease in glucose metabolism e.g. in the
parietal cortex with at the same time relatively preserved
Figure 4. A linear model of age and MMSE related changes observed in AD in MRI considering the healthy control group as
baseline. AD Alzheimer’s disease, MMSE Mini Mental State Examination, MRI structural magnetic resonance imaging.
doi:10.1371/journal.pcbi.1002987.g004
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metabolism in the temporal region would lead to an observation of
both regions when comparing younger patients to younger
controls. Yet, only the temporal region would be detected when
comparing older patients to older controls.
A third result is in the dissociation of age- and disease- related
processes inferred from the intersection ages of healthy aging and
AD models. While in previous research some studies successfully
applied whole-brain approaches to discriminate dementia patients
from control subjects [6,11,36], sparse solutions based on highly
discriminative features have been used in most [4,37–40].
However, there is a problem with feature selection that has been
neglected till now. This is the assumption of feature reliability,
independent of the expression of possible confounding variables.
We decided to investigate this assumption by testing whether a
correlation of AD symptom severity with imaging data was also
affected by the processes of normal aging as defined in a healthy
population. We did this with our described method of model
intersections. Our results suggest that features like local atrophy or
glucose hypometabolism that discriminate between AD patients
and control subjects at the age of 60 are not necessarily observed at
age 80. This non-stationarity of features is mainly explained by
atrophy and hypometabolism related to healthy aging, which
affect some regions similarly to AD. We previously demonstrated
that accounting for changes related to healthy aging improves AD
detection with support vector machine classification [19]. This
study extends that approach and suggests that diagnostic classifier
algorithms, like machine learning techniques, when applied to the
general population, need to take potential interactions of imaging
features with demographic and clinical factors into account.
Related to this, our intersection model also provides evidence that
the pathological pattern observed in AD in some regions is clearly
distinguishable from healthy aging even at very advanced age.
The obtained models could be used to improve early AD
detection e.g. by training automated classifiers on age- and
symptom severity- specific pathological AD patterns (features)
extracted by thresholding the obtained AD model. They could also
be applied directly in clinical assessment by evaluating the
similarity of observed pathology in any individual to age- and
symptom severity- specific patterns generated using the AD model.
Thereby, to enable individual assessment, percent signal difference
maps could be calculated between each subject’s imaging data and
imaging data generated using the healthy aging model. However,
both of these approaches require careful evaluation in future
studies prior to clinical application.
Nonetheless, a valid interpretation of our results needs to
consider the effects of several other assumptions and limitations.
First, the sensitivity of the generative model for detecting and
predicting AD pathology depends on the accuracy of the model of
healthy aging. The age- related, widespread patterns of brain
atrophy and hypometabolism we find are consistent with previous
findings [16,31,41–43]. The most prominent changes of glucose
hypometabolism we observed include large parts of an occipital-
parietal-frontal network. The only non-linear (quadratic) relation-
ship between age and metabolic changes we found in an
anatomically highly restricted area in the left dorsal parietal
cortex. The absence of more complex relationships between these
parameters indicates that linear models are very probably a
sufficient approximation of the underlying structural and meta-
bolic processes.
A major advantage of our approach is the generalizability of our
model to any constellation of age and symptom severity. A further
difference to conventional approaches is that the method we
propose relies on a voxel-wise group mean, ignoring the variance
and so allowing detection of quite minor group differences. This
type of analysis, though more flexible than conventional statistics,
nevertheless requires caution in the interpretation of results. Minor
differences between groups of healthy subjects and AD patients
could still be due to random effects unrelated to AD. However, as
Figure 5. Voxel-wise intersections of healthy aging and changes observed in AD in MRI (a) and FDG-PET (b). Colour bars represent
the intersection age. AD Alzheimer’s disease, FDG-PET [18F]fluorodeoxyglucose positron emission tomography, MRI structural magnetic resonance
imaging.
doi:10.1371/journal.pcbi.1002987.g005
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we model disease progression (albeit based on cross-sectional data)
we would expect the magnitude of differences to increase with
higher symptom severity. This assumption suggests that local
differences between AD patients and control subjects that are not
so correlated with it are more likely to be due to random artefacts
than disease related pathology.
For all three models used in our study, we made the assumption
that healthy aging affects AD patients in the same way as healthy
subjects in terms of hypometabolic and atrophic changes, with AD
pathology additive to changes associated with healthy aging. This
assumption is in line with current views that AD as a pathological
process is unrelated to healthy aging.
A further issue of interpretation of interactions is the recognised
inaccuracy of clinical diagnosis of AD, which may differ in
younger vs. older or in mildly vs. severely impaired patients. Any
bias towards an alternative diagnosis or co-diagnosis with another
dementing condition could lead to a different anatomical or
hypometabolic pattern. Such a differential pattern of glucose
hypometabolism was seen, for example, in sensorimotor regions
only in old AD patients with low symptom severity.
Most of these problems are also common to standard statistical
methods of evaluation of group differences. In group statistics one
often uses a high significance threshold to avoid false positive
results thus minimising their effect on between group differenti-
ations. By contrast, our approach also provides an opportunity to
evaluate the impact of possible confounding effects, such as age in
this case, on the discrimination between AD patients and control
subjects.
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